IGI Logo

Lupin is currently trading at Rs. 811.50, up by 7.85 points or 0.98% from its previous closing of Rs 803.65 on the BSE.

The scrip opened at Rs. 810.00 and has touched a high and low of Rs. 813.00 and Rs. 804.35 respectively. So far 8809 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 813.30 on 30-May-2023 and a 52 week low of Rs. 592.55 on 17-Jun-2022.

Last one week high and low of the scrip stood at Rs. 813.30 and Rs. 770.05 respectively. The current market cap of the company is Rs. 36571.10 crore.

The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.

Lupin has entered into strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab. This collaboration marks a significant milestone in expanding therapeutic options and fostering innovation in the critical area of treatment of head and neck cancer. Cetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer, particularly Squamous Cell Carcinoma of the Head andNeck (SCCHN), making it a crucial solution for patients with recurrent locoregional or metastatic conditions. Cetuximab is available as a 100mg vial.

Head and neck cancer presents a significant public health challenge in India, with a staggering annual incidence of over 100,000 new cases. This malignancy affects critical regions of the head and neck, including the oral cavity, pharynx, larynx, and sinuses. The disease is often diagnosed at advanced stages, making effective treatment increasingly challenging. As a result, head and neck cancer carries a substantial burden, leading to significant difficulties in providing effective treatment and resulting in high mortality rates.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India